Stocktwits on MSN

Cingulate stock jumps overnight: US Patent Office clears ADHD drug filing ahead of May FDA catalyst

The USPTO cleared a patent filed in November 2023, with a status indicating it has been approved and the patent is expected ...
Benzinga.com

What's Going On With Cingulate Shares Recently?

Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...
MM&M

Cingulate signs commercialization agreement with Indegene for ADHD drug

Biopharma company Cingulate announced a joint commercialization agreement with Indegene this week, which pushes forward Cingulate’s lead drug candidate for attention deficit/hyperactivity disorder ...
Benzinga.com

Cingulate Shares Are Trading By More Than 200% Friday: What You Need To Know

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
Hosted on MSN

Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential

Retail chatter around Cingulate picked up on Tuesday after Roth Capital Partners raised its price target to $17 from $10 and reaffirmed a ‘Buy’ rating. Cingulate Inc.’s stock snapped a two-day losing ...
Business Insider

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced ...
The Business Journals

Cingulate wins $3M from private foundation to help develop third time-release drug

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cingulate will use the money ...